Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen. - Wikidata - wikimedia - TriplyDB

Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen.

Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen.

http://www.wikidata.org/entity/Q34768999

about

Herbal Medicine for Hot Flushes Induced by Endocrine Therapy in Women with Breast Cancer: A Systematic Review and Meta-Analysis Psychiatric benefits of integrative therapies in patients with cancer.Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients Efficacy and safety of pharmacotherapy in cancer-related psychiatric disorders across the trajectory of cancer care: a review.Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen.The burden and management of cytochrome P450 2D6 (CYP2D6)-mediated drug-drug interaction (DDI): co-medication of metoprolol and paroxetine or fluoxetine in the elderly.Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch Pre-clinical evaluation of CYP 2D6 dependent drug-drug interactions between primaquine and SSRI/SNRI antidepressants.Association of CYP2D6*10 (c.100C>T) polymorphisms with clinical outcome of breast cancer after tamoxifen adjuvant endocrine therapy in Chinese population Psychopharmacology in psycho-oncology.Role of cytochrome P450 genes in breast cancer etiology and treatment: effects on estrogen biosynthesis, metabolism, and response to endocrine therapy.Methods: for studying pharmacogenetic profiles of combination chemotherapeutic drugs.Venlafaxine in management of hot flashes in women with breast cancer: a systematic review and meta-analysis.Potential risks associated with traditional herbal medicine use in cancer care: A study of Middle Eastern oncology health care professionals.ReCAP: Would Women With Breast Cancer Prefer to Receive an Antidepressant for Anxiety or Depression From Their Oncologist?Impact of a complementary/integrative medicine program on the need for supportive cancer care-related medications.Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen.

P2860

Q26740203-BF456A09-3683-4AA7-80B7-DE44F85B550D Q30361220-E118ECF0-5A8D-4488-983E-7658E136AF6C Q35056229-E35E67E5-74C6-42CA-9A4E-456EA5D4F3AA Q35092002-773C1847-2E01-4D5C-A920-1E1DC70DF4CA Q35143365-11A56D18-1C37-4780-97E0-C4AA40E42934 Q35884159-687D16E9-1346-4BA1-9DA8-22E782E5D55C Q36323469-C25F4976-C531-46DB-B32A-B56BA00D1312 Q36586900-6C3B99A2-C50B-4D14-8DD4-894DF4105E7E Q36907360-24009994-A078-4213-9ABE-10C19BBB9F21 Q37228037-C6B41401-A5F1-4725-91E8-4BBA7D2B9E76 Q38129301-45874B4B-3D02-4FE2-AA62-749078AD5C2D Q38305705-2416584E-18DB-46B2-9F03-8C6D82CE857E Q38513661-657ACF86-D2BD-489F-8281-7DDF93E78ECD Q38525755-07F979E6-6393-46B1-B45E-90EBA3E038F7 Q40283529-514DDC3C-052C-4BAF-A994-142A765E9F41 Q40964123-C718FB55-FE2C-490D-979C-6F004BF1ADF9 Q47901163-B45ECCA1-80C0-460E-A793-AD45CED5FF6D Q48125765-4F37372E-58FE-4281-BD26-95D0B6C33186

P2860

Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen.

http://www.wikidata.org/entity/Q34768999

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen.

@ast

Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen.

@en

Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen.

@nl

type

label

Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen.

@ast

Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen.

@en

Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen.

@nl

prefLabel

Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen.

@ast

Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen.

@en

Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen.

@nl

P1433

Q34768999-CC7D2BB8-23AA-4813-8BDC-39F9669E799A

P1476

Q34768999-2B5DCD2A-82F9-4D15-B269-0C0D11F51E7E

P2093

Q34768999-1ABC7B22-4837-4F8B-8244-FBEE86910CA4

Q34768999-5ED89B19-2373-45E1-9ACE-4F6205B8D066

Q34768999-708BCCDF-ECEC-4F56-A9D4-7E87414F347B

Q34768999-A4F4D506-7833-4DE8-938C-7ED887797B54

Q34768999-D1F4A240-0602-4DE3-B37A-564AB8D79671

Q34768999-DBA29796-1C1E-4FF3-8A1F-B338E9C4D504

Q34768999-E25FB4DA-FA81-4127-ABFF-A2A018AC2AAE

P2860

Q34768999-003292FF-5251-4B6C-9EC5-5ED7072EC98E

Q34768999-00E73364-560A-4A55-9AE3-F86818E939CD

Q34768999-051CC879-5DCC-4E3D-9746-E4DE73BD2F73

Q34768999-0B7EA466-5DA6-47E4-8067-6126CB096BA6

Q34768999-14BEA79A-6108-409D-B726-A9AC8F2E58FD

Q34768999-19505E37-FC4B-4C9C-89D2-16EDD431E7A1

Q34768999-1D27D9F3-23B9-405F-9421-BD8FCE8B9AD6

Q34768999-286EE3AC-1BB0-47F4-B0A4-A0B10879301E

Q34768999-46D6991F-0BA2-40C4-8C10-19FE65050E95

Q34768999-5AA1E182-77D3-4853-8425-EC4E93610296

P2888

Q34768999-17E292F5-B1C0-47AF-8995-2500AA35F693

P304

Q34768999-A49DDB8A-EB98-4341-82AE-C99E228DDE0E

P31

Q34768999-39855FEB-4BE1-4894-9B80-8AD53106D17B

P356

Q34768999-C0285D81-6FCF-4DBB-A84D-42A0BF5FF3AF

P407

Q34768999-DD88A33A-F5FF-48BF-B5D9-5C5FBDC62B05

P433

Q34768999-2855007C-6F98-4A3A-95E1-696D9D2B2726

P478

Q34768999-F87EB64E-FAD6-4CD1-B497-37B0232573D5

P577

Q34768999-34B5006D-267D-4741-8007-DB7AA4AA65A0

P6179

Q34768999-6CE97A16-E523-4123-91E4-2CD66276DF27

P698

Q34768999-17474743-8DF0-4621-8C04-8482F3DFCF4F

P356

S10549-013-2585-Z

P1433

Breast Cancer Research and Treatment

P1476

Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen.

@en

P2093

Agnes Jager

http://www.w3.org/2001/XMLSchema#string

Erik A C Wiemer

http://www.w3.org/2001/XMLSchema#string

Lisette Binkhorst

http://www.w3.org/2001/XMLSchema#string

Marjolein Bannink

http://www.w3.org/2001/XMLSchema#string

Myrthe P P van Herk-Sukel

http://www.w3.org/2001/XMLSchema#string

Ron H J Mathijssen

http://www.w3.org/2001/XMLSchema#string

Teun van Gelder

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

Nationwide drug-dispensing data reveal important differences in adherence to drug label recommendations on CYP2D6-dependent drug interactions.

Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study

Coprescription of tamoxifen and medications that inhibit CYP2D6.

Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment.

Effects of CYP induction by rifampicin on tamoxifen exposure.

Mechanisms of tamoxifen resistance.

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.

Individualization of tamoxifen treatment for breast carcinoma.

P2888

s10549-013-2585-z

P304

923-929

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-013-2585-Z

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

139

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1043416861

http://www.w3.org/2001/XMLSchema#string

P698

23760858

http://www.w3.org/2001/XMLSchema#string